H.C. Wainwright Reaffirms Buy on BioLineRx Ltd. (BLRX) After ASCO 2025

BioLineRx Ltd. (NASDAQ:BLRX) is among the best growth stocks to invest in for the next 5 years. H.C. Wainwright reaffirmed its Buy rating on BioLineRx Ltd. (NASDAQ:BLRX) while maintaining a price target of $26.00. This confidence follows the company’s participation in ASCO 2025, where the management presented full data from the pilot phase of its CheMo4METPANC Phase 2 trial.

While exhibiting superior efficacy in contrast to historical controls, the outcomes showcased an overall response rate and a disease control rate of 64% and 91%, respectively. What’s even more exciting is that four out of eleven patients remained progression-free even after a year of treatment. While one patient showed a complete radiologic resolution of liver metastases and secured definitive radiation to the primary pancreatic tumor, the other one maintained a sustained partial response, and upon undergoing pancreaticoduodenectomy, a complete response was noted.

These results set the foundation for the company to transform the trial into a randomized Phase 2 study with 108 patients. All of these efforts are a testament to the company’s strong footing in the coming years. Having said that, FTSE Russell recently announced the addition of BioLineRx Ltd. (NASDAQ:BLRX) to the Russell Microcap Index.

BioLineRx Ltd. (NASDAQ:BLRX) is a commercial-stage biopharmaceutical company that develops and commercializes therapeutics targeting oncology and rare diseases. Incorporated in 2003, the company is focused on fulfilling unmet medical needs through its drug development efforts.

While we acknowledge the potential of BLRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.